Ionis Pharmaceuticals, Inc. Stock price

Equities

IONS

US4622221004

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
42.03 USD -1.22% Intraday chart for Ionis Pharmaceuticals, Inc. -2.84% -16.92%
Sales 2024 * 635M Sales 2025 * 764M Capitalization 6.13B
Net income 2024 * -583M Net income 2025 * -523M EV / Sales 2024 * 9.29 x
Net cash position 2024 * 226M Net Debt 2025 * 170M EV / Sales 2025 * 8.24 x
P/E ratio 2024 *
-10.4 x
P/E ratio 2025 *
-11.9 x
Employees 927
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.69%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.22%
1 week-2.84%
Current month-7.03%
1 month-5.40%
3 months-17.12%
6 months-2.10%
Current year-16.92%
More quotes
1 week
41.68
Extreme 41.68
43.95
1 month
41.68
Extreme 41.68
47.66
Current year
41.68
Extreme 41.68
54.44
1 year
32.87
Extreme 32.87
54.44
3 years
25.04
Extreme 25.04
55.96
5 years
25.04
Extreme 25.04
86.58
10 years
19.59
Extreme 19.5927
86.58
More quotes
Managers TitleAgeSince
Founder 58 12-06-30
Founder 62 89-01-09
Director of Finance/CFO 62 00-04-30
Members of the board TitleAgeSince
Chairman 72 14-02-02
Founder 62 89-01-09
Director/Board Member 70 19-06-09
More insiders
Date Price Change Volume
24-03-18 42.03 -1.22% 968,336
24-03-15 42.55 +0.88% 1,251,368
24-03-14 42.18 -2.27% 1,324,844
24-03-13 43.16 -0.02% 1,110,600
24-03-12 43.17 -0.21% 798,887

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company is primarily focused on cardiovascular and neurology franchises. The Company's products include SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA is for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. TEGSEDI is for the treatment of patients with polyneuropathy caused by hereditary transthyretin (TTR), amyloidosis (hATTR), a debilitating, progressive, and fatal disease. WAYLIVRA is an antisense medicine indicated as an adjunct to diet in adult patients. The Company has over seven medicines in Phase III studies for nine indications, which include Eplontersen (TTR), Olezarsen (ApoC-III), Donidalorsen (PKK), ION363 (FUS), Pelacarsen (Apo(a)), Tofersen (SOD1) and Bepirovirsen. Its cardiovascular medicine in development includes Eplontersen, Olezarsen, Pelacarsen, Fesomersen, ION904 and IONIS-AGT-LRx.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
42.03 USD
Average target price
56.72 USD
Spread / Average Target
+34.94%
Consensus
  1. Stock
  2. Equities
  3. Stock Ionis Pharmaceuticals, Inc. - Nasdaq